Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL.
暂无分享,去创建一个
Subramaniam Pennathur | Andrew N Hoofnagle | Sina A. Gharib | P. Ridker | A. Chait | A. Hoofnagle | K. Elkon | S. Pennathur | J. Brunzell | T. Vaisar | S. Marcovina | J. Heinecke | X. Zhao | Pragya Singh | P. Green | J. Oram | Sina A Gharib | Pattie S Green | Xue-Qiao Zhao | Jaeman Byun | Santica Marcovina | Jay W Heinecke | Tomas Vaisar | S. Kassim | R. Knopp | M. Cheung | Paul Ridker | Jaeman Byun | R. Geary | Robert H Knopp | John F Oram | Pragya Singh | Keith Elkon | Alan Chait | Marian C Cheung | Simona Vuletic | Sean Kassim | Helen Chea | John Brunzell | Randolph Geary | S. Vuletic | Helen K. Chea
[1] I. Young,et al. High density lipoprotein subfractions: isolation, composition, and their duplicitous role in oxidation Published, JLR Papers in Press, October 25, 2006. , 2007, Journal of Lipid Research.
[2] Rebekah L. Gundry,et al. Investigation of an albumin‐enriched fraction of human serum and its albuminome , 2007, Proteomics. Clinical applications.
[3] D. Rader. Molecular regulation of HDL metabolism and function: implications for novel therapies. , 2006, The Journal of clinical investigation.
[4] J. Heinecke,et al. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. , 2006, Current opinion in cardiology.
[5] U. Smith,et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. , 2006, The New England journal of medicine.
[6] A. Tall,et al. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. , 2006, The Journal of clinical investigation.
[7] R. Mahley,et al. Putting cholesterol in its place: apoE and reverse cholesterol transport. , 2006, The Journal of clinical investigation.
[8] Steven V. Ley,et al. Targeting C-reactive protein for the treatment of cardiovascular disease , 2006, Nature.
[9] G. Hortin,et al. Diverse range of small peptides associated with high-density lipoprotein. , 2006, Biochemical and biophysical research communications.
[10] Farhad Rezaee,et al. Proteomic analysis of high‐density lipoprotein , 2006, Proteomics.
[11] A. Lucas,et al. Serpins, the vasculature, and viral therapeutics. , 2006, Frontiers in bioscience : a journal and virtual library.
[12] K. Resing,et al. Comparison of Label-free Methods for Quantifying Human Proteins by Shotgun Proteomics*S , 2005, Molecular & Cellular Proteomics.
[13] S. Hajduk,et al. Human High Density Lipoproteins Are Platforms for the Assembly of Multi-component Innate Immune Complexes* , 2005, Journal of Biological Chemistry.
[14] Eugene A. Kapp,et al. Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly‐available database , 2005, Proteomics.
[15] M. Heller,et al. Mass spectrometry‐based analytical tools for the molecular protein characterization of human plasma lipoproteins , 2005, Proteomics.
[16] J. Kaye,et al. Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro , 2005, Journal of neuroscience research.
[17] Per Leanderson,et al. Lipoproteomics II: Mapping of proteins in high‐density lipoprotein using two‐dimensional gel electrophoresis and mass spectrometry , 2005, Proteomics.
[18] Chang Yeop Han,et al. Thematic review series : The Immune System and Atherogenesis Lipoprotein-associated inflammatory proteins : markers or mediators of cardiovascular disease ? , 2005 .
[19] D. Hoyert,et al. Deaths: preliminary data for 2003. , 2005, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[20] K. Resing,et al. Proteomics strategies for protein identification , 2005, FEBS letters.
[21] A. Boodhoo,et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. , 2005, Clinical chemistry.
[22] Donna L. Hoyert,et al. Deaths: preliminary data for 2003 (USA) , 2005 .
[23] P. Barter,et al. Antiinflammatory Properties of HDL , 2004 .
[24] A. Chait,et al. Human Atherosclerotic Intima and Blood of Patients with Established Coronary Artery Disease Contain High Density Lipoprotein Damaged by Reactive Nitrogen Species* , 2004, Journal of Biological Chemistry.
[25] R. Aebersold,et al. A Dataset of Human Liver Proteins Identified by Protein Profiling Via Isotope-coded Affinity Tag (ICAT) and Tandem Mass Spectrometry*S , 2004, Molecular & Cellular Proteomics.
[26] V. Hascall,et al. Inter-α-trypsin Inhibitor, a Covalent Protein-Glycosaminoglycan-Protein Complex* , 2004, Journal of Biological Chemistry.
[27] A. Chait,et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[28] Michael Kinter,et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. , 2004, The Journal of clinical investigation.
[29] V. Schumaker,et al. Virtual two‐dimensional gel electrophoresis of high‐density lipoproteins , 2004, Electrophoresis.
[30] E. Birney,et al. The International Protein Index: An integrated database for proteomics experiments , 2004, Proteomics.
[31] J. Yates,et al. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. , 2004, Analytical chemistry.
[32] G. Getz,et al. Paraoxonase, a cardioprotective enzyme: continuing issues , 2004, Current opinion in lipidology.
[33] Aldons J Lusis,et al. Thematic review series: The Pathogenesis of Atherosclerosis Published, JLR Papers in Press, April 1, 2004. DOI 10.1194/jlr.R400001-JLR200 The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL , 2004, Journal of Lipid Research.
[34] V. Hascall,et al. Inter-alpha-trypsin inhibitor, a covalent protein-glycosaminoglycan-protein complex. , 2004, The Journal of biological chemistry.
[35] Bing Zhang,et al. GOTree Machine (GOTM): a web-based platform for interpreting sets of interesting genes using Gene Ontology hierarchies , 2004, BMC Bioinformatics.
[36] Gil Atzmon,et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. , 2003, JAMA.
[37] John R Yates,et al. Reproducibility of quantitative proteomic analyses of complex biological mixtures by multidimensional protein identification technology. , 2003, Analytical chemistry.
[38] P. Kovanen,et al. Role of complement activation in atherosclerosis , 2003, Current opinion in lipidology.
[39] Douglas A. Hosack,et al. Identifying biological themes within lists of genes with EASE , 2003, Genome Biology.
[40] R. Aebersold,et al. A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.
[41] A. Burlingame,et al. Human apoC-IV: isolation, characterization, and immunochemical quantification in plasma and plasma lipoproteins. , 2003, Journal of lipid research.
[42] E. Arias,et al. Deaths: preliminary data for 2011. , 2012, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[43] A. Tall,et al. Regulation and mechanisms of macrophage cholesterol efflux. , 2002, The Journal of clinical investigation.
[44] D. Mangelsdorf,et al. Regulated Expression of the Apolipoprotein E/C-I/C-IV/C-II Gene Cluster in Murine and Human Macrophages , 2002, The Journal of Biological Chemistry.
[45] P. Ridker,et al. Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study☆ , 2001 .
[46] A. Chait,et al. Biglycan, a Vascular Proteoglycan, Binds Differently to HDL2 and HDL3: Role of ApoE , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[47] J. Blake,et al. Creating the Gene Ontology Resource : Design and Implementation The Gene Ontology Consortium 2 , 2001 .
[48] P. Stetson,et al. Rabbit Serum Paraoxonase 3 (PON3) Is a High Density Lipoprotein-associated Lactonase and Protects Low Density Lipoprotein against Oxidation* , 2000, The Journal of Biological Chemistry.
[49] N. Baroukh,et al. Expression of Human Apolipoprotein A-I/C-III/A-IV Gene Cluster in Mice Induces Hyperlipidemia but Reduces Atherogenesis , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[50] S. Wright,et al. Fibrinogen is a component of a novel lipoprotein particle: factor H-related protein (FHRP)-associated lipoprotein particle (FALP). , 2000, Blood.
[51] B. Dahlbäck,et al. A Novel Human Apolipoprotein (apoM)* , 1999, The Journal of Biological Chemistry.
[52] J. Yates,et al. Direct analysis of protein complexes using mass spectrometry , 1999, Nature Biotechnology.
[53] E. Braunwald. Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. , 1997, The New England journal of medicine.
[54] P. Duchateau,et al. Apolipoprotein L, a New Human High Density Lipoprotein Apolipoprotein Expressed by the Pancreas , 1997, The Journal of Biological Chemistry.
[55] R. Havel,et al. Identification, Characterization, Cloning, and Expression of Apolipoprotein C-IV, a Novel Sialoglycoprotein of Rabbit Plasma Lipoproteins (*) , 1996, The Journal of Biological Chemistry.
[56] J. Kane,et al. Identification of proteins associated with apolipoprotein A-I-containing lipoproteins purified by selected-affinity immunosorption. , 1994, Biochemistry.
[57] H. Wilson,et al. Alterations in the concentration of an apolipoprotein E-containing subfraction of plasma high density lipoprotein in coronary heart disease. , 1993, Clinica chimica acta; international journal of clinical chemistry.
[58] Jing Zhao,et al. Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement. Affinity of the apoproteins for polymeric C9. , 1993, The Journal of biological chemistry.
[59] J P Kane,et al. Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[60] A. Mendez,et al. Protein kinase C as a mediator of high density lipoprotein receptor-dependent efflux of intracellular cholesterol. , 1991, The Journal of biological chemistry.
[61] M J Davies,et al. A macro and micro view of coronary vascular insult in ischemic heart disease. , 1990, Circulation.
[62] A. Tall,et al. Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. , 1990, The Journal of clinical investigation.
[63] D. Gordon,et al. High-density lipoprotein--the clinical implications of recent studies. , 1989, The New England journal of medicine.
[64] P. Wilson,et al. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. , 1988, Arteriosclerosis.
[65] M. Cheung,et al. Differential effect of ultracentrifugation on apolipoprotein A-I-containing lipoprotein subpopulations. , 1988, Journal of lipid research.
[66] G. Anantharamaiah,et al. Characterization of high density lipoprotein subspecies: structural studies by single vertical spin ultracentrifugation and immunoaffinity chromatography. , 1987, Journal of lipid research.
[67] J. Kane,et al. Characteristics of human lipoproteins isolated by selected-affinity immunosorption of apolipoprotein A-I. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[68] R. Strunk,et al. Human peripheral blood monocyte-derived macrophages produce haemolytically active C3 in vitro. , 1983, Immunology.